Angio

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that the company's licensee, AnGes MG,Inc. reported positive results following interim analysis of datafrom the first 41 subjects to complete a Phase 3 trial of anangiogenesis product candidate using Vical's DNA deliverytechnology. Based on the findings that the primary efficacyendpoint in the trial had...

Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference

Pre-clinical Data Suggests Angiolix Can Inhibit Breast CancerGrowth By 75% DALLAS and IRVINE, Calif., June 04, 2007 /PRNewswire-FirstCall/-- Access Pharmaceuticals, Inc. (Bulletin Board: ACCP) and SomantaPharmaceuticals, Inc. (Bulletin Board: SMPM) announced today that ascientific abstract outlining new preclinical efficacy data forSomanta's Angiolix has been selected for publication in t...

Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. ("Lev" or the "Company") announced today thatit has completed patient treatment in the prophylactic portion ofits Phase III clinical trial of C1-esterase inhibitor (C1-INH) forhereditary angioedema (HAE). The clinical trial, designated CHANGE,examined and evaluated the efficacy and safety of C1-INHreplacement thera...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of HypertensionTreatment Valsartan in Preventing Cardiovascular Events in JapanesePatients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinicaloutcomes of the JIKEI HEART Study, the large-scale clinical trialheaded by the Jikei University School of Medicine, was todaypublished in the internationally renowned medical journal TheLancet. The...

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a globalspecialty pharmaceutical and medical device company, announced thatthe two-year data from its European pivotal trial examining theVascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)")will be presented today at a scientific forum in Europe. Thetwo-year study examine...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp.(Nasdaq:DYAX) announced today positive topline results from itsPhase 3, placebo-controlled trial, EDEMA3, for its lead productcandidate DX-88 (ecallantide), for hereditary angioedema (HAE). Awebcast presentation of the EDEMA3 data is scheduled for Tuesday,April 17, 2007 at 12:30 p.m. ET. DX-88, an internally discovered, recombina...

Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group

Major Bleeding in Patients Treated for Acute Coronary Syndromes(ACS) Nearly Triples the Risk of Death at One Year NEW ORLEANS, March 26, 2007 /PRNewswire/ -- One-year findingsfrom the landmark ACUITY trial show that acute coronary syndrome(ACS) patients in the "Angiomax(R) (bivalirudin) alone" treatmentgroup had similar rates of ischemic clinical outcomes compared withmore complicated sta...

Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema

Company anticipates second quarter BLA filing for C1-inhibitorreplacement therapy NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. (Lev) today announced positive results fromits pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH)for the acute treatment of hereditary angioedema (HAE). In theacute study, which is part of the company's CHANGE trials(C1-...